Journal of Clinical Anesthesia (2011) 23, 153–165

Review article

Perioperative pulmonary embolism: diagnosis and

anesthetic management
Matthew C. Desciak MD (Resident), Donald E. Martin MD (Professor)⁎
Department of Anesthesiology, Penn State University College of Medicine, Hershey, PA 17033, USA

Received 1 May 2009; revised 18 June 2010; accepted 29 June 2010

Keywords:
Abstract All perioperative patients, but especially trauma victims and those undergoing prostate or
Anesthesia;
orthopedic surgery, are at increased risk of venous thromboembolism. Patients at highest risk include
Intraoperative
those with malignancy, immobility, and obesity; those who smoke; and those taking oral
complications;
contraceptives, hormone replacement therapy, or antipsychotic medications. Dyspnea, anxiety, and
Postoperative
tachypnea are the most common presenting symptoms in awake patients, and hypotension, tachycardia,
complications;
hypoxemia, and decreased end-tidal CO2 are the most common findings in patients receiving general
Pulmonary embolism;
anesthesia. The presence of shock and right ventricular failure are associated with adverse outcomes.
Thromboembolism
Helical computed tomographic scanning is the preferred definitive diagnostic study, but transesopha-
geal echocardiography may be valuable in making a presumptive diagnosis in the operating room. Early
diagnosis allows supportive therapy and possible anticoagulation (in some cases, to be started before
the conclusion of surgery).
© 2011 Elsevier Inc. All rights reserved.

1. Introduction presents with hemodynamic instability and it is more likely

Surgery puts patients at increased risk for pulmonary
embolism (PE). Anesthesiologists may find themselves
responsible for the diagnosis and management of this
sometimes fatal disorder. Further, the diagnosis is often
one of exclusion and may be obscured intraoperatively by
much more common disorders, including bleeding and
infection. The ongoing surgical procedure may limit initial
management options.
The diagnosis and treatment of PE in medical patients
recently was reviewed by Wood [1] and Tapson [2].
Pulmonary embolism presents different challenges in
surgical patients. At the time of surgery, PE often first
⁎ Corresponding author. Tel.: +1 717 531 6140; fax: +1 717 531 0997.
E-mail address: dmartin1@psu.edu (D.E. Martin).
to follow a rapid course, leading to death within several
hours. Prompt diagnosis and management, however, may
reduce morbidity and mortality.
2. Incidence in surgical patients
There is as great as a fivefold increase in the incidence of
PE during and after surgery [3,4]. Surgical patients have
many patient-specific risk factors for PE, in addition to risk
factors unique to the perioperative experience, including the
acute inflammatory reaction caused by tissue trauma,
activation of the clotting cascade, and immobilization/
venous stasis. In Goldhaber et al.'s series, 50% of the
perioperative patients who suffered perioperative PE had
received thromboembolism prophylaxis [5]. Table 1 shows

0952-8180/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.jclinane.2010.06.011
154 M.C. Desciak, D.E. Martin

Table 1 Incidence of perioperative pulmonary embolus (PE) by type of surgical procedure

Surgical population Incidence of PE Incidence of fatal PE
General surgery 1.6% (average) [4,6] 0.9% (average) [4]
Thoracic 1.5%-2% [109,110] 0.34%-1.2% [13,110]
Abdominal 0.32%-1.0% [13,111] 0.03%-0.4% [13,111]
Laparoscopic 0.06%-0.9% [13-16] 0-0.02% [15,16]
Vascular 0.4%-0.7% [112,113] 0.1%-0.2% [112,113]
Head and neck 0.4%-0.44% [114,115] 0.06% [114]
Gynecologic 0.3%-4.1% [116] 0.4% [3]
Ortho: THA 0.7%-30% [4] 0.1%-0.4% [4]
Ortho: TKA 1.8%-7% [4] 0.2%-0.7% [4]
Ortho: hip fracture repair 4.3%-24% [4] 3.6%-12.9% [4]
Urologic 0.9%-1.1% [117-119] b 0.2% [4]
Neurosurgical 0-4% [120-122] 0.13-1% [121,123,124]
Trauma 2.3%-6.2% [105,125] 0.4-2% [4]
Acute SCI 4.6%-9% [126,127] 3%-5% [128-130]
The incidence of pulmonary embolism during and following hospitalization in patients undergoing various types of surgical procedures, including patients
with and without preoperative deep vein thrombosis (DVT) prophylaxis.
THA = total hip arthroplasty, TKA = total knee arthroplasty, SCI = spinal cord injury.

the incidence of PE associated with various surgical
procedures. Pulmonary embolism occurs in approximately
0.3% to 1.6% of the general surgical population [3,4,6,7]. In
2009, Beyer et al. reported that the incidence of PE after
prostate procedures was 5.8% [8]. The incidence of PE has
been quoted as 0.7% to 30% after all orthopedic surgical
procedures, and 4.3% to 24% following hip fracture repair,
primarily as a result of the location of the surgical procedure,
which may distort the femoral vein, leading to impaired
venous return and stasis [9]. Most series do not distinguish
between emboli occurring during and after surgery, but
Koessler et al. reviewed 4 series of patients undergoing
total hip arthroplasty and found that the incidence of
symptomatic intraoperative PE was between 0.6% and 10%
[10]. Mortality associated with perioperative PE is as high
as 12.9% in patients presenting for hip fracture repair
[4,11]. However, both Kerkez et al. and Milbrink and
Bergqvist recently found a much lower incidence of
symptomatic emboli, approximately 0.25%, in patients
receiving thromboembolism prophylaxis following hip
fracture surgery [7,12].
In contrast to the high rate of perioperative PE in
orthopedic patients, laparoscopic procedures have been
associated with a low incidence of both non-fatal and fatal
PE [13-16]. This decrease has been hypothesized to occur
secondary to less surgical trauma, earlier ambulation, as well
as a less pronounced prothrombotic state in laparoscopic than
open surgical procedures [17].
Some of the variation in incidence of postoperative PE
over the past 10 years may be attributed to advances in the
detection of smaller and more peripheral emboli. Auer et al.
[18] found that the incidence of postoperative PE increased
from 2.3 to 9.3 per 1,000 in unselected cancer patients during
the years from 2000 to 2005. This increase correlated with an
increase in the use of spiral (helical) computed tomographic
(CT) scans from 6.6 scans per 1,000 postoperative patients in
2000 to 45 scans per 1,000 postoperative patients in 2005,
and it was attributed almost entirely to improved detection.
The increased detection was limited to segmental and
subsegmental emboli. Some 10.7% of the patients diagnosed
in 2005 were asymptomatic. The incidence of fatal PE in this
series remained constant at 0.4 per 1,000 patients each year,
implying that there was no change in the incidence of severe
emboli [18].
3. Pathophysiology
3.1. Changes in pulmonary function and gas exchange
Abnormalities in respiratory function and pulmonary gas
exchange are some of the first changes seen when venous
emboli lodge in the lungs. They have been attributed to an
increase in alveolar dead space, or more directly to right-to-
left shunting and V/Q mismatch, which may be conse-
quences of the physical obstruction to blood flow caused by
the emboli themselves. As blood flow is shunted away from
the obstructed pulmonary arteries (PAs), it then causes over-
perfusion of the rest of the lung tissue, leading to edema, loss
of surfactant, and alveolar hemorrhage. The resulting
atelectasis develops acutely but may remain long after the
emboli themselves resolve and the lung is reperfused [1].
Hypoxia due to pulmonary changes may be much more
severe in the presence of a probe-patent foramen ovale,
opened by the elevated right atrial (RA) pressure and causing
a large interatrial shunt. In patients with low cardiac output
(CO), low mixed venous pO2 may exacerbate the effects of
shunt or V/Q mismatch on arterial oxygenation. However,
augmentation of CO with inotropes also may decrease pO2
Anesthesia and perioperative PE
by increasing shunt blood flow. Regional hypocarbia may
lead to bronchoconstriction, as may humoral mediators such
as serotonin released from platelet-rich emboli [19].
3.2. Circulatory changes
The initial hemodynamic insult with PE is obstruction to
blood flow caused by emboli in the pulmonary vasculature
and pulmonary outflow tract, leading to an acute increase in
right ventricular (RV) impedance. Right ventricular outflow
impedance also may be increased by preexisting pulmonary
disease, as well as by neural reflexes and the release of
pulmonary vasoconstrictors into the circulation. Pulmonary
vasoconstrictors such as serotonin and platelet-activating
factor originate from platelets trapped in the emboli
themselves. Vasoactive peptides such as activated comple-
ment factors 3 and 5 come from plasma, and histamine
comes from tissue mast cells [1]. The acute increase in
pulmonary vascular resistance and RV afterload may start
the cycle of deleterious circulatory changes shown in Fig. 1.
Because of its geometry, the RV is much more sensitive to
pressure than to volume loads. Therefore, increases in
pressure load will lead to significant decreases in RV stroke
volume (SV). To maintain CO, the body's initial response is
catecholamine-mediated tachycardia and an increase in RA
Fig. 1 Pathophysiology of major pulmonary embolus. Effects of increase in pulmonary vascular resistance and right ventricular (RV)
afterload. CPP = coronary perfusion pressure, CO/MAP = cardiac output/mean arterial pressure, LV = left ventricle. From: Wood KE.
Pulmonary embolism: review of a pathophysiologic approach to the golden hour of a hemodynamically significant pulmonary embolism.
Chest 2002;121:877-905 [1], with permission.
155
pressure and RV preload, in an attempt to return SV to
normal. However, increasing RV preload often leads
primarily to RV dilation and subsequent leftward shift in
the interventricular septum, limiting left ventricular (LV)
filling. With continued increase in RV afterload and
pressure, and especially in the face of RV ischemia, the
RV begins to fail and CO begins to decrease. As the RV
pumps less blood through the constricted pulmonary vessels,
LV preload will decrease, decreasing LV output to the
systemic circulation. Initially catecholamine-induced vaso-
constriction will increase systemic vascular resistance and
maintain systemic arterial pressure (BP). However, further
decrease in CO leads to systemic hypotension.
Right ventricular dilation and increased RV afterload both
lead to an increase in the RV wall stress, which can be
determined by Laplace's Law, as applied to thin-walled
structures such as the RV [20]:
pressure x radius
Wall stress ¼
2 x wall thickness
Since wall stress is an important determinant of RV
oxygen demand, increased wall stress, especially if coupled
with systemic hypotension and decreased coronary perfusion
pressure (CPP), may precipitate RV ischemia, and even
infarction [21].
156 M.C. Desciak, D.E. Martin

Table 2 Hemodynamic consequences of a major pulmonary embolus compared with common alternative diagnoses
Blood Right atrial Pulmonary artery Pulmonary vascular Left atrial Cardiac Systemic vascular
pressure pressure pressure resistance pressure output resistance
Hypovolemia ↓ ↓ ↓ ± ↓ ↓ ↑
Sepsis ↓ ↓ ↓ ± ↓ ↑ ↓↓
Left ventricular failure ↓ ↑ ↑ ± ↑↑ ↓ ↑
Pulmonary embolism ↓ ↑ ↑↑ ↑↑ ↓ ↓ ↑
↑increase, ↑↑ large increase, ↓decrease, ↓↓ large decrease, ± small or no change.

The hemodynamic changes associated with PE are 4. Patient risk factors

summarized and compared with those of other common
causes of hypotension (Table 2). More than 100 years ago, Virchow described his now
famous triad of risk factors for venous thromboembolism
(VTE): venous stasis, endothelial damage, and a hyperco-
agulable state [22]. All risk factors for PE may in some way
Table 3 Patient risk factors for venous thromboembolism and be traced back to this central concept. Table 3 provides an
pulmonary embolism extensive list of risk factors, and it is clear that many of these
Hereditary risks are present in the surgical patient. Patients with
⦁ Antithrombin deficiency malignancy deserve special attention. They have increased
⦁ Protein C deficiency risks associated with malignancy secondary to induction of a
⦁ Protein S deficiency hypercoagulable state caused by both hormones released
⦁ Factor V Leiden from the tumor and certain chemotherapeutic agents. Patients
⦁ Prothrombin gene deficiency with cancer are also affected by reduced mobility, frequent
Acquired
presence of indwelling central venous catheters, as well as
⦁ Advanced age
⦁ Cancer
possible venous obstruction from tumor. Cancer is such a
⦁ Reduced mobility strong risk factor for VTE that a recent meta-analysis by
⦁ Acute medical illness (CHF, respiratory failure) Carrier et al. showed that cancer patients have 30 VTE events
⦁ Inflammatory bowel disease per 100 patient years compared with 12.8 events per 100
⦁ Nephrotic syndrome patient years in the general population [23], and the rate of
⦁ Pregnancy/postpartum period PE in cancer patients with an indwelling central venous
⦁ Central venous catheterization catheter has been estimated at 15% to 25% [24]. A
⦁ Trauma prospective study by Goldhaber et al. showed that obesity
⦁ Spinal cord injury (BMI N 29 kg/m2) and smoking (N 35 cigarettes/day) were
⦁ Obesity independent risk factors of PE in women, with a relative risk
⦁ Previous venous thromboembolism
of PE of 2.9 and 3.3, respectively [25].
⦁ Tobacco use
Medications
Certain medications also may induce a hypercoagulable
⦁ Heparins state in patients. Specifically, the risk of PE in women using
⦁ Hormone replacement therapy second-generation oral contraceptives is three times greater
⦁ Oral contraceptives than in non-users [26], and hormone replacement therapy is
⦁ Chemotherapy associated with an approximately twofold increase in the risk
⦁ Antipsychotics of PE [27-29]. A recent study by Lacut et al. showed a 3.5-
Surgery fold increase in the rate of VTE in patients taking
⦁ “Major surgery”-loosely defined (includes most open antipsychotic medications [30].
abdominal and thoracic procedures)
⦁ Fracture (hip or leg)
⦁ Hip or knee replacement
4.1. Effects of anesthetic on risk
⦁ General anesthesia (when compared with epidural/spinal for
lower abdominal and lower extremity surgery) The choice of anesthetic technique may have a profound
Adapted from: Tapson VF. Acute pulmonary embolism. N Engl J
impact on the patient's risk for VTE. A meta-analysis by
Med 2008;358:1037-52 [2] (© 2008, Massachusetts Medical Society, Rodgers et al. comparing epidural anesthesia (either as the
all rights reserved), and Anderson FA Jr, Spencer FA. Risk factors for primary anesthetic or as an adjunct to general anesthesia)
venous thromboembolism. Circulation 2003;107(23 Suppl 1):I9-I16 with general anesthesia alone, showed a 44% and 55%
[131], with permission. reduction in the rates of deep vein thrombosis (DVT) and PE,
CHF = congestive heart failure.
respectively, for the epidural group [31]. A second meta-
Anesthesia and perioperative PE
analysis investigated the impact of continuous lumbar
epidural on thromboembolic complications in hip surgery,
knee surgery, prostatectomy, and lower extremity vascular
surgery, finding a 34% reduction in events in the epidural
group [32]. However, when this same meta-analysis looked
at the impact of thoracic epidurals in major abdominal and
thoracic surgery, no significant difference was seen in the
epidural group. This difference in epidural effect is presumed
to be caused by the fact that thoracic epidurals have a less
profound effect on lower extremity blood flow and venous
stasis than lumbar epidurals [32].
5. Diagnosis
5.1. Physical findings
While the common presenting symptoms in awake
patients are often helpful in the initial diagnosis of PE,
they are masked in the anesthetized, mechanically ventilated
patient. The anesthesiologist then must rely on other findings
that may still appear in unconscious patients. Hypotension
and tachycardia are the classic intraoperative findings
associated with PE [33].
Kasper et al. found that 59% of hospitalized patients
with major PE presented with significant hemodynamic
instability–18% presenting in cardiac arrest and 10% with
hypotension requiring vasopressor support [34]. Prominent
physical findings that may be obtained by the anesthesi-
ologist include an arterial pulse that is sharp and of small
volume, tachycardia (HR N 100 bpm), elevated jugular
venous pressure, a gallop rhythm at the left sternal edge,
and an accentuated second heart sound [21]. Wheezing has
been cited frequently as a physical finding that may be
present in acute PE. However, wheezing is present to the
same extent in patients with proven PE and those in whom
PE has been ruled out [35] Table 4.
The presence of shock is an early and reliable predictor of
mortality in patients with acute PE, regardless of whether the
shock is caused primarily by a massive PE or a smaller PE in
Table 4 Clinical findings at diagnosis in patients with major
pulmonary embolism
Dyspnea 96%
Tachycardia 71%
Acute onset of symptoms (b 48 hrs) 70%
Age N 65 yrs 52%
Syncope 35%
Arterial hypotension (SBP b 90 mmHg) 34%
Adapted from Kasper W, Konstantinides S, Geibel A, et al. Management
strategies and determinants of outcome in acute major pulmonary
embolism: results of a multicenter registry. J Am Coll Cardiol
1997;30:1165-71, with permission.
SBP = systolic blood pressure.
157
patients with severe preexisting cardiopulmonary disease.
Kucher et al. found an almost fourfold increase in all-cause,
90-day mortality in patients presenting in shock compared
with normotensive patients [36]. Toosi et al. found that a
“shock index” (HR/systolic blood pressure) N 1 had a
significant positive association with inhospital mortality and
was helpful in triaging patients with acute PE into high and
low-risk groups [37]. Furthermore, patients presenting in
shock are much more likely to die in the first hour [1];
diagnosis and institution of therapy must be much more rapid
than for hemodynamically stable patients.
5.2. Intraoperative diagnostic tests
In the best of circumstances, PE is a diagnosis of
exclusion. During and after anesthesia and surgery, diagnosis
may be even more difficult. However, common intraopera-
tive monitors and diagnostic studies, perhaps modified
slightly and coupled with a high index of suspicion, may
lead to at least a presumptive diagnosis, even during surgery.
This early diagnosis is invaluable in planning management
and reducing morbidity.
5.2.1. Electrocardiography
Most patients with PE exhibit some abnormalities on
electrocardiography (ECG). Geibel et al. found sinus
tachycardia and atrial arrhythmias in 83% of patients with a
confirmed diagnosis of PE; atrial arrhythmias, in particular,
were associated with a higher mortality rate [38]. Other
common ECG findings associated with PE are ST segment
and T wave abnormalities. Non-specific ST changes, ST
elevation and depression, or T wave inversion, are found in
approximately 50% of patients. Complete right bundle
branch block and T wave inversions in the precordial leads
are the findings that correlate best with severity of PE [38-40].
The ECG findings of acute cor pulmonale, such as right-
axis deviation, complete or incomplete right bundle branch
block, the S1Q3T3 pattern (Fig. 2), P-pulmonale, and
anterior T wave inversions are associated with RV
dysfunction and correlated strongly with short-term and
30-day mortality [38,41].
However, serious rhythm disturbances are uncommon.
Atrial fibrillation/flutter; first, second, or third degree heart
block; as well as ventricular dysrhythmias, are present in less
than 5% to 10% of patients [42].
5.2.2. Arterial blood gases
The usual arterial blood gas (ABG) changes found in
spontaneously breathing patients with PE are hypoxemia,
respiratory alkalosis, and hypocapnea. Systemic arterial
hypoxemia is the most sensitive manifestation of PE and is
perhaps the only ABG abnormality in patients with
obstruction of 25% or less [43]. In patients with no prior
cardiopulmonary disease, room air PO2 was less than 80
mmHg in 74% [42], and the severity of the PE had an inverse
linear relationship to the arterial PO2 [43]. Patients with a
158
Fig. 2 S1Q3T3 pattern. From: Stead LG, Stead SM, Kaufman MS. First Aid for the Emergency Medicine Clerkship: A Student Guide. New
York: McGraw-Hill; 2001. p. 118 [132], with permission.
room air oxygen saturation of less than 95% at the time of
diagnosis had a higher incidence of complications [44].
5.2.3. Physiologic dead space
An increase in physiologic dead space is almost
invariably associated with pulmonary thromboembolism. In
a small study of 12 surgical patients with PE, Anderson et al.
found that dead space showed 100% sensitivity and 89%
specificity in predicting the diagnosis [45]. The ratio of
physiologic dead space to tidal volume may be calculated
using the Bohr equation:
Vd phys ¼ VT ½ðPaCO2 −PeCO2 Þ=PaCO2 
where Vd phys is the physiologic dead space, VT is the tidal
volume, PeCO2 is the mixed expired PCO2, and PaCO2 is the
arterial PCO2. Arterial PCO2 may be measured directly.
However, to determine the mixed expired PCO2, exhaled
PCO2 must usually be analyzed in a mixing box, a Douglas
bag must be used, or the mixed expired PCO2 must be
calculated by commercially available devices that integrate
instantaneous PCO2 over an entire breath (Nico monitor;
Nova Metrix Medical Systems, Wallingford, CT, USA).
None of these devices is readily available in most operating
rooms (ORs).
However, several authors have discussed practical
methods to at least estimate the mixed expired PCO2 or the
physiologic dead space. Most recently, in 2007, Badel and
Loeb described a simple method to estimate mixed expired
PCO2 using a standard anesthesia breathing circuit [46].
M.C. Desciak, D.E. Martin
They threaded a “side stream” PCO2 sampling line into the
ventilator bellows of the anesthesia machine through an
adapter placed between the bellows and the breathing circuit,
and used this sampling line to measure PCO2 of the gas
within the bellows, which corresponded to the mixed exhaled
PCO2 within ± 12%, even with high fresh gas flows. At fresh
gas flows less than 2,000 mL/min, the accuracy of the
measurement was even greater. Using this device along with
measured arterial PCO2, the Vd/Vt and especially changes in
Vd/Vt may be calculated intraoperatively.
In 1976, Sahn et al. discussed a simple but more empirical
method of predicting elevations in dead space, assuming
normal CO2 production. Using their method, in an adult, if
Ve x PaCO2 N 8 x (patient body weight in kg), it is likely that
the dead space is elevated [47].
5.2.4. Laboratory studies
D-dimer, and especially the enzyme-linked immunoab-
sorbent assay (ELISA), is a sensitive but very nonspecific test
for PE. The ELISA assay has a sensitivity of 96% to 98%,
but it also may be positive in conditions unrelated to PE,
including infection, cancer, trauma, surgery itself, and other
inflammatory states. Therefore, a negative d-dimer study is
helpful in ruling out PE in patients with a low clinical
suspicion. However, an elevated d-dimer is of little help in
supporting a diagnosis of PE or estimating its severity [2].
Serum troponin I and troponin T are elevated in less than
50% of patients with an acute, moderate to large PE, so they
are not very helpful in making this diagnosis. However,
elevation of these markers is associated with adverse
Anesthesia and perioperative PE
outcomes, including death, and the need for catecholamines
and resuscitation [2,48].
Finally, the levels of brain naturetic peptide (BNP) may
be elevated in PE, but these are likely caused by RV
dilation and thus are also elevated in many other conditions,
such as heart failure, which could cause ventricular dilation
[49,50]. Sohne et al. found a sensitivity and specificity of
only 60% and 62%, respectively, for BNP in hemodynam-
ically stable patients with acute PE [51], limiting its
diagnostic usefulness.
5.2.5. Chest radiograph
Elliott et al. found that cardiomegaly is the most
common finding on chest radiograph in patients with PE
[52]. Although the chest radiograph is usually not very
helpful in establishing a diagnosis of PE, it may either
support or rule out alternative causes of hypoxemia and
hypotension, such as pneumothorax, pleural effusion,
pneumonia, atelectasis, aspiration, or heart failure, which
were found on the chest radiograph in more than 50% of
patients with a presentation concerning for PE [42].
5.2.6. Confirmatory diagnostic tests
If the patient is not actually undergoing surgery and is
hemodynamically stable, several options are available to
confirm or rule out PE. Traditionally, V/Q scan has been
considered the first-line test. However, the vast majority of
V/Q scans in the 1990 Prospective Investigation of
Pulmonary Embolism Diagnosis (PIOPED) study were
non-diagnostic, with only 15% being “normal” and 13%
being “high probability” [53], leaving 72% as “indetermi-
nant”. More recently, single photon emission computed
tomography (SPECT) imaging has improved the predictive
value of V/Q scans, with only 1% now nondiagnostic [54].
Angiography has long been considered the “gold
standard” for the diagnosis of PE. It is expensive, invasive,
and not uniformly available. It is also not without risk. Stein
et al. showed a 4% incidence of major complications
(including death and renal failure) in the intensive care
population undergoing angiography [55].
Spiral, or helical, CT scanning continues to gain favor
because it is noninvasive, comparably inexpensive, and
readily available. The overall sensitivity for detecting PE
with spiral CT is approximately 85% [56,57]. A pooled
analysis of several large series by Wood [1] showed that
spiral CT is considerably more sensitive (94%) and specific
(94%) for detecting PE in the central arteries. In cases of PE
that are associated with hemodynamic instability or evidence
of RV overload, the sensitivity and specificity of spiral CT
approach 100% [58-60]. Pooled analysis of more than 2,500
patients by Schoepf et al. showed greater than 99% negative
predictive value associated with a normal spiral CT scan
[61]. Auer et al. in 2009, showed that spiral CT scanning
significantly increased the likelihood of a diagnosis of
segmental and subsegmental PE in postoperative cancer
patients. As was mentioned earlier, the study was so sensitive
159
in their series that 10.7% of patients in whom spiral CT scan
diagnosed peripheral PE were asymptomatic [18].
Echocardiography is not the preferred test to confirm the
presence of PE. Rosenberger et al. showed that an embolus
was visible on transesophageal echocardiography (TEE) in
only 26% of patients with severe PE [62]. However, TEE
may be particularly useful to the anesthesiologist as it is
readily available and may be performed in the OR without
interrupting the surgical procedure. The speed and accuracy
of TEE renders it an attractive choice, as shown by
Pruszczyk et al. These researchers showed that, in an
average examination time of 9.6 minutes, TEE had a
sensitivity of 80.5% and a specificity of 97.2% in a patient
population with clinical suspicion of PE and evidence of
RV strain [58]. Pruszczyk et al. also showed that TEE
compared favorably with spiral CT in establishing the
diagnosis of acute, central PE [58,63]. Rosenberger et al.
found that TEE detected RV dysfunction in 96%, tricuspid
regurgitation in 50%, and leftward atrial septal bowing in
98% of patients with PE that was severe enough to require
surgery [62].
In assessment of PE, RV dilation is the most common
finding on TEE. However, at least 30% obstruction of the
pulmonary vasculature is required to produce RV dilation
[1]. Further, RV dilation may result from other disease
states such as cor pulmonale with pulmonary hypertension,
RV infarction, or chronic/recurrent PE [64]. Kasper et al.
showed that RV dilation associated with cor pulmonale or
chronic/recurrent PE was associated with RV hypertrophy,
while RV dilation from acute PE or RV infarct was not. In
addition, ventricular septal shift is commonly seen in acute
PE and not in RV infarct [64]. Table 5 highlights some of
the more common echocardiographic findings associated
with PE [65,66]. Moderate to severe RV hypokinesis
following PE, with an RV/LV diastolic diameter ratio N 1
on TEE, has been associated with significantly higher in
hospital morbidity [37,67].
Table 5 Echocardiographic findings associated with
pulmonary embolism
RV/LV end-diastolic diameter ratio N 0.7
RV/LV area ratio N 0.66
RV end-diastolic diameter N 27 mm
“McConnell sign” ⁎
Septal shift
Tricuspid regurgitation N 270 cm/sec
Adapted from Lodato JA, Ward RP, Lang RM. Echocardiographic
predictors of pulmonary embolism in patients referred for helical CT.
Echocardiography 2008;25:584-90 [65], with permission; and Nazeyr-
ollas P, Metz D, Chapoutot L, et al. Diagnostic accuracy of
echocardiography-Doppler in acute pulmonary embolism. Int J Cardiol
1995;47:273-80 [66], with permission.
RV/LV = right ventricular/left ventricular.
⁎ Presence of RV-free wall hypokinesis or akinesis coupled with
RV apex normokinesis or hyperkinesis.
160
In addition to aiding in the diagnosis of PE, TEE is useful
in establishing alternative diagnoses such as aortic dissec-
tion, pericardial disease, hypovolemia, myocardial dysfunc-
tion/infarction, and valvular insufficiency [1,63], as well as
guiding therapy in the resuscitation of hemodynamically
unstable patients [68].
6. Prophylaxis of deep vein thrombosis/
pulmonary embolism
6.1. Pharmacologic prophylaxis
The 2008 guidelines for the prevention of VTE by the
American College of Chest Physicians recommend that
patients undergoing major general surgery receive throm-
boprophylaxis in the form of either low-molecular-weight
heparin (LMWH), low-dose unfractionated heparin (LDUH),
or fondaparinux. Patients undergoing major gynecologic or
major, open urologic procedures should receive either
LMWH, LDUH, fondaparinux, or intermittent pneumatic
compression. All major trauma patients and patients with
spinal cord injury, as well as other spinal and neurosurgery
patients with risk factors for thromboembolism, should
have mechanical prophylaxis with sequential compression
during surgery, and then pharmacoprophylaxis begun
postoperatively [4].
Orthopedic surgery patients are at a notably high risk for
perioperative VTE and as such prophylaxis in this group
deserves special attention. It is recommended that patients
undergoing elective hip or knee replacement receive either
LMWH, fondaparinux, or warfarin (with INR 2-3), while
patients having hip fracture repair should receive either
LMWH, fondaparinux, warfarin, or LDUH [4]. Prophylaxis
with warfarin should begin the night before surgery.
Prophylaxis with LMWH or LDUH should begin either 12
hours before surgery or 4 to 24 hours postoperatively. For
patients receiving fondaparinux, therapy should begin 6 to
8 hours postoperatively. Each of these groups of patients
should receive thromboprophylaxis for a minimum of 10
days postoperatively, and patients undergoing hip arthro-
plasty or hip fracture repair should continue this therapy for
up to 35 days [4].
Low-molecular-weight heparin has become a popular
choice for VTE prophylaxis because, in most instances, it
does not require laboratory monitoring of levels [2,4,69].
There is less need for monitoring because the antithrombotic
response to weight-based dosing is more predictable than
with unfractionated heparin (UFH), owing to the smaller
molecular size of LMWH. The smaller size results in less
charge-related protein binding and improved subcutaneous
bioavailability [69]. Because LMWH is cleared by the
kidneys, it is recommended that UFH be used instead of
LMWH in patients with creatinine clearance b 30 mL/min. If
LMWH is used in this patient population, it is recommended
M.C. Desciak, D.E. Martin
that lower doses be used and/or anti-Xa levels be followed
[4,69]. Less predictable bioavailability also may be encoun-
tered in morbidly obese (N 150 kg), very thin (b 40 kg), or
pregnant patients, and therefore anti-Xa levels should be
considered in these patients as well [69].
Fondaparinux is a relatively new anticoagulant that binds
antithrombin III, increases its activity, and inhibits factor Xa
but has no direct activity against thrombin. It is rapidly
absorbed, has near 100% bioavailability, and a half-life of 15
hours that renders it suitable for once daily dosing [70,71].
Fondaparinux is also associated with a lower incidence of
heparin-induced thrombocytopenia [72]. Fondaparinux, like
LMWH, is eliminated by the kidneys and similar precautions
should be taken in dosing for patients with renal failure [4,73].
6.2. Mechanical prophylaxis
While it is generally less efficacious than pharmacologic
means of prophylaxis [74], mechanical prophylaxis such as
intermittent pneumatic compression devices, reduces the
incidence of VTE by as much as 60% when compared with
no prophylaxis [75,76]. Mechanical prophylaxis is the
thromboprophylaxis method of choice in patients with a
high risk of bleeding or for patients in whom bleeding would
be catastrophic, such as neurosurgical patients [4].
6.2.1. Vena cava filters
The role of vena cava filters in the prophylaxis of PE in
high-risk patients, such as those with recent trauma, is
controversial. While some studies have suggested that filters
reduce the incidence of PE [77,78], no reduction in mortality
has been shown, and the presence of a vena cava filter
increases the risk of recurrent DVT by as much as 9%
[79,80]. Considering the lack of convincing data, the current
recommendation by the American College of Chest
Physicians is against the routine use of vena cava filters for
prophylaxis in trauma patients [81]. The data are too limited
to make a recommendation either for or against vena cava
filters in other patient populations, so these must be decided
on a case-by-case basis. Vena cava filters probably should be
reserved for patients at risk for VTE with contraindications to
anticoagulation, bleeding complications from anticoagula-
tion, or recurrent PE in spite of adequate anticoagulation [2].
7. Supportive therapy
The initial therapy for PE may be started before a definitive
diagnosis is established or even before the patient leaves the
OR, beginning with supportive therapy aimed at stabilizing the
patient and minimizing the effect of the embolic occlusion.
Vasopressors should be used with the goal of improving RV
function and contracting the systemic vasculature to maintain
BP and CPP in the face of a fixed obstruction to blood flow
caused by the emboli. Wood [1] suggests that norepinephrine
Anesthesia and perioperative PE
may be the pressor of choice for the treatment of hypotension
in patients with massive PE. The beneficial effect of
norepinephrine may be due, first, to its α-1 mediated
vasoconstriction, which increases BP and RV CPP, as well
as increasing venous return. In addition, β1 stimulation by
norepinephrine enhances both RV and LV contractility and
CO. Alternatives to norepinephrine include dopamine,
epinephrine, and dobutamine [82]. However, dobutamine
may cause unwanted peripheral vasodilation via a β2
mechanism, and also may decrease arterial oxygenation by
changing the V/Q relationships [82,83]. Combined treatment
with dobutamine and norepinephrine may be considered.
Pulmonary vasodilators such as inhaled nitric oxide may
be useful in decreasing PA pressures, increasing CO, and
improving RV function and pulmonary gas exchange in
patients with PE, without significantly decreasing systemic
BP [84].
8. Anticoagulant and thrombolytic therapy
The perioperative treatment of documented or suspected
PE is complicated by an increased risk of bleeding
complications, which usually precludes the immediate use
of pharmacologic anticoagulants in surgical patients. Most
patients should be managed on a case-by-case basis after
discussion with the surgical team. The following therapeutic
modalities are available for the management of acute PE.
8.1. Anticoagulation
The treatment of PE with pharmacologic anticoagulation
has been supported since 1960, when a significant reduction
in both mortality and recurrence was seen with UFH versus
Table 6 Anticoagulant treatment for acute pulmonary embolism [69,81,89]
IV Unfractionated heparin (UFH)
SC UFH (unmonitored)
SC UFH (monitored)
SC LMWH
SC Fondaparinux
Warfarin
IV = intravenous, SC = subcutaneous, BID = twice daily, APTT = activated partial thromboplastin time, LMWH = low-molecular-weight heparin,
QD = once daily.
⁎ For an average 70 kg adult.
161
no treatment [85]. While not directly thrombolytic, anti-
coagulants allow the body's intrinsic fibrinolytic system to
function unopposed, decreasing the thromboembolic burden
[2]. Intravenous (IV) or subcutaneous (SC) UFH, SC
LMWH, and SC fondaparinux may be used in the initial
treatment of acute, non-massive PE [86-89]. The current
recommendation by the American College of Chest
Physicians is for the use of SC LMWH rather than IV
UFH as the initial treatment of acute, non-massive PE [81].
There are, however, certain situations in which IV UFH is
preferred because of its shorter duration of action and quick
titratability: acute, massive PE, situations with potential for
decreased SC absorption, and in patients in whom thrombo-
lysis is being considered or planned [69,81]. Unfractionated
heparin also may be preferred in patients with renal
insufficiency or morbid obesity, those are who are very
thin, or pregnant. The recommended doses and routes of
these medications are shown in Table 6.
8.2. Thrombolysis
Thrombolysis for the initial treatment of PE is somewhat
controversial. Few studies have directly compared throm-
bolysis with IV UFH. While the older literature showed that
thrombolysis leads to earlier reversal of RV dysfunction
when compared with heparin alone [90], a review in 2006
showed no clear benefit of thrombolytic therapy when
compared with heparin in the treatment of acute PE [91]. A
large meta-analysis by Wan et al. [92] showed a
nonsignificant decrease in mortality and increase in major
bleeding in all patients with PE who were treated with
thrombolysis, not heparin. When this same meta-analysis
focused on just patients with major PE, however, the
decrease in mortality to 6.2% with thrombolysis, compared
Bolus: 80 U/kg, or 5,000 U ⁎
Infusion: 18 U/kg/hr or 1,300 U/hr ⁎
(adjust to APTT equivalent to 0.3 to 0.7
IU/mL anti-Xa activity)
Initial bolus: 333 U/kg
Maintenance: 250 U/kg BID
Maintenance: 250 U/kg BID (adjust to APTT
equivalent to 0.3 to 0.7 IU/mL anti-Xa activity
measured 6 hours after injection)
Enoxaparin 100 IU/kg BID or 150 IU/kg QD
Dalteparin 100 IU/kg BID or 200 IU/kg QD
Tinzaparin 175 IU/kg QD
b 50 kg: 5 mg QD
50-100 kg: 7.5 mg QD
N 100 kg: 10 mg QD
Transition to warfarin therapy when patient
taking oral and other medications started.
162
with 12.7% in the heparin group, was statistically
significant. Nevertheless, in this subgroup of patients the
risk of major bleeding was also increased to 21.9%,
compared with 11.9% in the heparin group [92]. The risk
of major bleeding cannot be understated. The risk of
intracranial hemorrhage associated with thrombolysis is as
high as 3% in a large registry compared with 0.3% in
patients who were not treated with thrombolysis [5]. The
recommendation of the American College of Chest
Physicians is against the use of thrombolytics in most
patients presenting with PE. Patients who may benefit from
thrombolysis are those who present with hemodynamic
compromise and are judged not to be at high risk of
bleeding [81].
8.3. Vena cava filter
Similar to its role in the prevention of PE, the vena cava
filter does have a clearly defined role in the treatment of
documented or suspected PE. Vena cava filters should be
used in the treatment of PE in patients for whom the risk of
bleeding is deemed too high to begin anticoagulation. As
with prophylactic placement, initiation of a traditional course
of anticoagulation is recommended when the bleeding risk
resolves [81].
8.4. Pulmonary embolectomy
Surgical embolectomy for PE was first described by
Trendelenburg [93] in 1908; Cooley et al. introduced
pulmonary embolectomy with cardiopulmonary bypass in
1961 [94]. The indication for surgical embolectomy remains
limited to patients with hemodynamic compromise who have
failed thrombolysis or have contraindications to thrombolysis
[81]. Since 2000, the mortality associated with pulmonary
embolectomy has been cited as 6% to 27% [95-98],
representing a significant decline from earlier reports of 30%
to 55% mortality [99-102].
Catheter-directed intervention with either suction embo-
lectomy/fragmentation or catheter-directed thrombolysis is a
relatively new technique that is effective in treating
hemodynamically significant PE after failed systemic
thrombolysis or as a first-line therapy in patients with
contraindications to systemic thrombolysis [103]. The role of
catheter-directed techniques has not been studied directly in
postoperative patients, but it is clearly an important
technique to consider in a hemodynamically unstable patient
who is not a candidate for systemic thrombolysis due to
recent major surgery.
9. Sequelae of pulmonary emboli
Despite therapy with heparin, oral anticoagulants, and
even thrombolytics and vena cava filters in some cases, acute
PE has been associated with a 15.3% to 25.3% three-month
M.C. Desciak, D.E. Martin
mortality [5,104] with up to 25% to 32% mortality in patients
presenting with RV failure requiring inotropic support
[34,105]. Increased mortality is associated with age N 70
years, congestive heart failure, chronic obstructive pulmo-
nary disease, and higher ASA physical status. Other adverse
prognostic factors in patients undergoing noncardiac surgery
are hypotension and tachypnea at presentation [106], RV
hypokinesis, longer surgical time, recent central venous
access, and intraoperative blood transfusion [104].
9.1. Recurrent venous thromboembolism
Several studies, the most recent one published by Pengo
et al. in 2004 [107], have found the rate of recurrent VTE to
be approximately 2.6% to 6.5% within the first 6 months,
and 8% to 8.3% within the first year of an initial embolic
event. Patients in Pengo et al.'s series all received warfarin
treatment for at least 6 months following the initial embolus.
In 2006, Schulman et al. found a 29% recurrence rate during
the first 10 years following an initial embolus in patients, all
of whom received warfarin anticoagulation following their
initial event. The rate of recurrence in their series was higher
among men, older patients, and those whose initial event was
triggered by a permanent factor, as opposed to a temporary
factor such as surgery or trauma. A larger proportion of the
recurrences (73%) were in patients with prior PEs rather than
in patients with prior DVT only (20%). The recurrence rate
was not changed by extending the duration of warfarin
prophylaxis from 6 weeks to 6 months [108].
Eighty to 85% of patients with acute PE, especially those
who receive adequate anticoagulant therapy, will survive the
initial event. These patients are at risk of two sequelae: 1)
chronic thromboembolic pulmonary hypertension and 2)
postthrombotic syndrome. Both sequelae are due to chronic
vascular changes that follow the presence of thrombi or
emboli, even in the face of post-event anticoagulation therapy.
10. Conclusion
Pulmonary embolism occurs with some frequency in
perioperative patients, and should be included in the
differential diagnosis of perioperative hypoxemia, hypoten-
sion, tachycardia, or acute reduction in end-tidal CO2.
Hemodynamic instability is a major risk factor in perioperative
patients with PE. Nevertheless, it is often possible to make at
least a presumptive diagnosis of PE, and even to begin
effective therapy in the OR or early postoperative period.
References
[1] Wood KE. Pulmonary embolism: review of a pathophysiologic
approach to the golden hour of a hemodynamically significant
pulmonary embolism. Chest 2002;121:877-905.
[2] Tapson VF. Acute pulmonary embolism. N Engl J Med 2008;358:
1037-52.
Anesthesia and perioperative PE
[3] Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous
thromboembolism. Chest 2001;119(1 Suppl):132S-75S.
[4] Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest
Physicians. Prevention of venous thromboembolism: American
College of Chest Physicians Evidence-Based Clinical Practice
Guidelines (8th Edition). Chest 2008;133(6 Suppl):381S-453S.
[5] Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism:
clinical outcomes in the International Cooperative Pulmonary
Embolism Registry (ICOPER). Lancet 1999;353(9162):1386-9.
[6] Qadan M, Tyson M, McCafferty MH, Hohmann SF, Polk HC Jr.
Venous thromboembolism in elective operations: balancing the
choices. Surgery 2008;144:654-60.
[7] Kerkez MD, Culafic DM, Mijac DD, Rankovic VI, Lekic NS,
Stefanovic DZ. A study of pulmonary embolism after abdominal
surgery in patients undergoing prophylaxis. World J Gastroenterol
2009;15:344-8.
[8] Beyer J, Wessela S, Hakenberg OW, et al. Incidence, risk profile and
morphological pattern of venous thromboembolism after prostate
cancer surgery. J Thromb Haemost 2009;7:597-604.
[9] Arcelus JI, Kudrna JC, Caprini JA. Venous thromboembolism
following major orthopedic surgery: what is the risk after discharge?
Orthopedics 2006;29:506-16.
[10] Koessler MJ, Fabiani R, Hamer H, Pitto RP. The clinical relevance of
embolic events detected by TEE during cemented total hip
arthroplasty: a randomized clinical trial. Anesth Analg 2001;92:
49-55.
[11] Hope WW, Demeter BL, Newcomb WL, et al. Postoperative
pulmonary embolism: timing diagnosis, treatment, and outcomes.
Am J Surg 2007;194:814-9.
[12] Milbrink J, Bergqvist D. The incidence of symptomatic venous
thromboembolic events in orthopaedic surgery when using routine
thromboprophylaxis. Vasa 2008;37:353-7.
[13] Sakon M, Kakkar AK, Ikeda M, et al. Current status of pulmonary
embolism in general surgery in Japan. Surg Today 2004;34:805-10.
[14] Inderbitzin DT, Opitz I, Giger U, Kocher T, Krähenbühl L. Incidence
of clinical pulmonary embolism after laparoscopic surgery. Br J Surg
2007;94:599-603.
[15] Lindberg F, Bergqvist D, Rasmussen I. Incidence of thromboembolic
complications after laparoscopic cholecystectomy: review of the
literature. Surg Laparosc Endosc 1997;7:324-31.
[16] Gargiulo NJ 3rd, Veith FJ, Lipsitz EC, et al. The incidence of
pulmonary embolism in open versus laparoscopic gastric bypass. Ann
Vasc Surg 2007;21:556-9.
[17] Prisco D, De Gaudio AR, Carla R, et al. Videolaparoscopic
cholecystectomy induces a hemostasis activation of lower grade
than does open surgery. Surg Endosc 2000;14:170-4.
[18] Auer RC, Schulman AR, Tuorto S, et al. Use of helical CT is
associated with an increased incidence of postoperative pulmonary
emboli in cancer patients with no change in the number of fatal
pulmonary emboli. J Am Coll Surg 2009;208:871-80.
[19] Elliott CG. Pulmonary physiology during pulmonary embolism.
Chest 1992;101(4 Suppl):163S-71S.
[20] Marcus JT, Gan CT, Zwanenburg JJ. Interventricular mechanical
asynchrony in pulmonary arterial hypertension: left-to-right delay in
peak shortening is related to right ventricular overload and left
ventricular underfilling. J Am Coll Cardiol 2008;51:750-7.
[21] Goldhaber SZ. Deep venous thrombosis and pulmonary embolism.
In: Braunwald E, Kasper DL, Hauser SL, Jameson JL, Loscal Fanci
AS, editors. Harrison's Principles of Internal Medicine, 17th edn.
New York: McGraw Hill; 2008. p. 1651-7.
[22] Vircow R. Gesammalte abhandlungen zur wissenschaftlichen
medizin. Frankfurt a Main, Germany: Medinger Sohn and Co.;
1856. p. 219-732.
[23] Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA.
Systematic review: the Trousseau Syndrome revisited: should we
screen extensively for cancer patients with venous thromboembo-
lism? Ann Intern Med 2008;149:323-33.
163
[24] Verso M, Agnelli G. Venous thromboembolism associated with long-
term use of central venous catheters in cancer patients. J Clin Oncol
2003;21:3665-75.
[25] Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study
of risk factors for pulmonary embolism in women. JAMA 1997;277:
642-5.
[26] Goldhaber S. Pulmonary embolism. N Eng J Med 1998;339:93-104.
[27] Vandenbroucke JP, Helmerhorst FM. Risk of venous thrombosis with
hormone replacement therapy. Lancet 1996;348(9033):972.
[28] Beral V, Banks E, Reeves G. Evidence from randomised trials on the
long-term effects of hormone replacement therapy. Lancet 2002;360
(9337):942-4.
[29] Sare GM, Gray LJ, Bath PM. Association between hormone
replacement therapy and subsequent arterial and venous vascular
events: a meta-analysis. Eur Heart J 2008;29:2031-41.
[30] Lacut K, LeGal G, Couturaud F, et al. Association between
antipsychotic drugs, antidepressant drugs and venous thromboem-
bolism: results for the EDITH case control study. Fundam Clin
Pharmacol 2007;21:643-50.
[31] Rodgers A, Walker N, Schug S, et al. Reduction of postoperative
mortality and morbidity with epidural or spinal anaesthesia: results
from overview of randomised trials. BMJ 2000;321(7275):1493-7.
[32] Kehlet H, Holte K. Effect of postoperative analgesia on surgical
outcome. Br J Anaesth 2001;87:62-72.
[33] Capan LM, Miller SM. Monitoring for suspected pulmonary
embolism. Anesthesiol Clin North America 2001;19:673-703.
[34] Kasper W, Konstantinides S, Geibel A, et al. Management strategies
and determinants of outcome in acute major pulmonary embolism:
results of a multicenter registry. J Am Coll Cardiol 1997;30:1165-71.
[35] Stein PD, Beemath A, Matta F, et al. Clinical characteristics of
patients with acute pulmonary embolism: data from PIOPED II. Am J
Med 2007;120:871-9.
[36] Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary
embolism. Circulation 2006;113:577-82.
[37] Toosi MS, Merlino JD, Leeper KV. Prognostic value of the shock
index along with transthoracic echocardiography in risk stratification
of patients with acute pulmonary embolism. Am J Cardiol 2008;101:700-5.
[38] Geibel A, Zehender M, Kasper W, Olschewski M, Klima C,
Konstantinides SV. Prognostic value of the ECG on admission in
patients with acute major pulmonary embolism. Eur Respir J
2005;25:843-8.
[39] Ferrari E, Imbert A, Chevalier T, Mihoubi A, Morand P, Baudouy M.
The ECG in pulmonary embolism. Predictive value of negative T
waves in precordial leads-80 case reports. Chest 1997;111:537-43.
[40] Yoshinago T, Ikeda S, Nishimura E, et al. Serial changes in negative
T wave on electrocardiogram in acute pulmonary thromboembolism.
Int J Cardiol 1999;72:65-72.
[41] Toosi MS, Merlino JD, Leeper KV. Electrocardiographic score and
short-term outcomes of acute pulmonary embolism. Am J Cardiol
2007;100:1172-6.
[42] Stein PD, Terrin ML, Hales CA, et al. Clinical, laboratory,
roentgenographic and electrocardiographic findings in patients with
acute pulmonary embolism and no pre-existing cardiac or pulmonary
disease. Chest 1991;100:598-603.
[43] McIntyre KM, Sasahara AA. The hemodynamic response to
pulmonary embolism in patients without cardiopulmonary disease.
Am J Cardiol 1971;28:288-94.
[44] Kline JA, Hernandez-Nino J, Newgard CD, Cowles DN, Jackson RE,
Courtney DM. Use of pulse oximetry to predict in-hospital
complications in normotensive patients with pulmonary embolism.
Am J Med 2003;115:203.
[45] Anderson JT, Owings JT, Goodnight JE. Bedside noninvasive
detection of acute pulmonary embolism in critically ill surgical
patients. Arch Surg 1999;134:869-74.
[46] Badel JJ, Loeb RG, Trujillo DK. A simple method to determine
mixed exhaled CO2 using a standard breathing circuit. Anesth Analg
2007;105:1048-52.
164
[47] Sahn SA, Lakshminarayan S, Petty TL. Weaning from mechanical
ventilation. JAMA 1976;235:2208-12.
[48] Pruszczyk P, Bochowicz A, Torbicki A, et al. Cardiac troponin T
monitoring identifies high-risk group of normotensive patients with
acute pulmonary embolism. Chest 2003;123:1947-52.
[49] Ray P, Delerme S, Jourdain P, Chenevier-Gobeaux C. Differential
diagnosis of acute dyspnea: the value of B naturetic peptides in the
emergency department. QJM 2008;101:831-43.
[50] Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of
patients with acute pulmonary embolism. Circulation 2003;108:2191-4.
[51] Söhne M, Ten Wolde M, Boomsma F, Reitsma JB, Douketis JD,
Büller HR. Brain naturetic peptide in hemodynamically stable acute
pulmonary embolism. J Thromb Haemost 2006;4:552-6.
[52] Elliott CG, Goldhaber SZ, Visani L, DeRosa M. Chest radiographs in
acute pulmonary embolism. Results from the International Cooper-
ative Pulmonary Embolism Registry. Chest 2000;118:33-8.
[53] Value of the ventilation/perfusion scan in acute pulmonary embolism:
results from the prospective investigation of pulmonary embolism
diagnosis (PIOPED). The PIOPED Investigators. JAMA 1990;263:2753-9.
[54] Bajc M, Olsson B, Palmer J, Jonson B. Ventilation/Perfusion SPECT
for diagnostics of pulmonary embolism in clinical practice. J Intern
Med 2008;264:379-87.
[55] Stein PD, Athanasoulis C, Alavi A, et al. Complications and validity
of pulmonary angiography in acute pulmonary embolism. Circulation
1992;85:462-8.
[56] Indik JH, Alpert JS. Detection of pulmonary embolism by D-dimer
assay, spiral computed tomography, and magnetic resonance
imaging. Prog Cardiovasc Dis 2000;42:261-72.
[57] Torbicki A. Imaging venous thromboembolism with emphasis on
ultrasound, chest CT, angiography and echocardiography. Thromb
Haemost 1999;82:907-12.
[58] Pruszczyk P, Torbicki A, Pacho R, et al. Noninvasive diagnosis of
suspected severe pulmonary embolism: transesophageal echocardi-
ography vs spiral CT. Chest 1997;112:722-8.
[59] Remy-Jardin M, Remy J, Wattinne L, Giraud F. Central pulmonary
thromboembolism: diagnosis with spiral volumetric CT with the
single-breath-hold technique–comparison with pulmonary angiogra-
phy. Radiology 1992;185:381-7.
[60] Teigen CL, Maus TP, Sheedy PF 2nd, et al. Pulmonary embolism:
diagnosis with contrast-enhanced electron-beam CT and comparison
with pulmonary angiography. Radiology 1995;194:313-9.
[61] Schoepf UJ, Goldhaber SZ, Costello P. Spiral computed tomography
for acute pulmonary embolism. Circulation 2004;109:2160-7.
[62] Rosenberger P, Shernan SK, Body SC, Eltzschig HK. Utility of
intraoperative transesophageal echocardiography for diagnosis of
pulmonary embolism. Anesth Analg 2004;99:12-6.
[63] Pruszczyk P, Torbicki A, Kuch-Wocial A, Chlebus M, Miśkiewicz
ZC, Jedrusik P. Transoesophageal echocardiography for definitive
diagnosis of haemodynamically significant pulmonary embolism.
Eur Heart J 1995;16:534-8.
[64] Kasper W, Geibel A, Tiede N, et al. Distinguishing between acute and
subacute massive pulmonary embolism by conventional and Doppler
echocardiography. Br Heart J 1993;70:352-6.
[65] Lodato JA, Ward RP, Lang RM. Echocardiographic predictors of
pulmonary embolism in patients referred for helical CT. Echocardi-
ography 2008;25:584-90.
[66] Nazeyrollas P, Metz D. Chapoutot, et al. Diagnostic accuracy of
echocardiography-Doppler in acute pulmonary embolism. Int J
Cardiol 1995;47:273-80.
[67] ten Wolde M, Söhne M, Quak E, MacGillavry MR, Büller HR.
Prognostic value of echocardiographically assessed right ventricular
dysfunction in patients with pulmonary embolism. Arch Intern Med
2004;164:1685-9.
[68] van der Wouw PA, Koster RW, Delemarre BJ, de Vos R, Lampe-
Schoenmaeckers AJ, Lie KI. Diagnostic accuracy of transesophageal
echocardiography during cardiopulmonary resuscitation. J Am Coll
Cardiol 1997;30:780-3.
M.C. Desciak, D.E. Martin
[69] Tran H, McRae S, Ginsberg J. Anticoagulant treatment of deep vein
thrombosis and pulmonary embolism. Cardiol Clin 2008;26:235-50.
[70] Turpie AG, Eriksson BI, Lassen MR, Bauer KA. Fondaparinux, the first
selective factor Xa inhibitor. Curr Opin Hematol 2003;10:327-32.
[71] Rawat A, Huynh TT, Peden EK, Kougias P, Lin PH. Primary
prophylaxis of venous thromboembolism in surgical patients. Vasc
Endovascular Surg 2008;42:205-16.
[72] Girolami B, Girolami A. Heparin-induced thrombocytopenia: a
review. Semin Thromb Hemost 2006;32:803-9.
[73] Tran AH, Lee G. Fondaparinux for prevention of venous thromboem-
bolism in major orthopedic surgery. Ann Pharmacother 2003;37:1632-43.
[74] Iorio A, Agnelli G. Low-molecular-weight and unfractionated
heparin for prevention of venous thromboembolism in neurosurgery:
a meta-analysis. Arch Intern Med 2000;160:2327-32.
[75] Urbankova J, Quiroz R, Kucher N, Goldhaber SZ. Intermittent
pneumatic compression and deep vein thrombosis prevention: a meta-
analysis in postoperative patients. Thromb Haemost 2005;94:1181-5.
[76] Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S,
Lonner JH. A meta-analysis of thromboembolic prophylaxis
following elective total hip arthroplasty. J Bone Joint Surg Am
2000;82-A:929-38.
[77] Cherry RA, Nichols PA, Snavely TM, David MT, Lynch FC.
Prophylactic inferior vena cava filters: do they make a difference in
trauma patients? J Trauma 2008;65:544-8.
[78] Velmahos GC, Kern J, Chan LS, Oder D, Murray JA, Shekelle P.
Prevention of venous thromboembolism after injury: an evidenced-
based report-part II. analysis of risk factors and evaluation of the role
of vena caval filters. J Trauma 2000;49:140-4.
[79] Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena
cava filters in the prevention of pulmonary embolism in patients with
proximal deep-vein thrombosis. Prévention du Risque d'Embolie
Pulmonaire par Interruption Cave Study Group. N Engl J Med
1998;338:409-15.
[80] Girard TD, Philbrick JT, Fritz Angle J, Becker DM. Prophylactic
vena cava filters for trauma patients: a systematic review of the
literature. Thromb Res 2003;112:261-7.
[81] Kearon C, Kahn SR, Agnelli G, et al. American College of Chest
Physicians. Antithrombotic therapy for venous thromboembolic
disease: American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):
454S-545S.
[82] Manier G, Castaing Y. Influence of cardiac output on oxygen exchange
in acute pulmonary embolism. Am Rev Respir Dis 1992;145:130-6.
[83] Jardin F, Genevray B, Brun-Ney D, Margairaz A. Dobutamine: a
hemodynamic evaluation in pulmonary embolism shock. Crit Care
Med 1985;13:1009-12.
[84] Capellier G, Gacques T, Balvay P, Blasco G, Belle E, Barale F.
Inhaled nitric oxide in patients with pulmonary embolism. Intensive
Care Med 1997;23:1089-92.
[85] Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of
pulmonary embolism. A controlled trial. Lancet 1960;1(7138):1309-12.
[86] Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight
heparin compared to intravenous unfractionated heparin for the
treatment of pulmonary embolism: a meta-analysis of randomized
controlled trials. Ann Intern Med 2004;140:175-83.
[87] Prandoni P, Carnovali M, Marchiori A; Galilei Investigators. A
subcutaneous adjusted-dose unfractionated heparin versus fixed-dose
low-molecular-weight heparin in the initial treatment of venous
thromboembolism. Arch Intern Med 2004;164:1077-83.
[88] Kearon C, Ginsberg JS, Julian JA, et al; Fixed-Dose Heparin (FIDO)
Investigators. Comparison of fixed-dose weight-adjusted unfractio-
nated heparin and low-molecular-weight heparin for acute treatment
of venous thromboembolism. JAMA 2006;296:935-42.
[89] Buller HR, Davidson BL, Decousus H, et al; Matisse Investigators.
Subcutaneous fondaparinux versus intravenous unfractionated hep-
arin in the initial treatment of pulmonary embolism. N Engl J Med
2003;349:1695-702.
Anesthesia and perioperative PE
[90] Come PC, Kim D, Parker JA, Goldhaber SZ, Braunwald E, Markis
JE. Early reversal of right ventricular dysfunction in patients with
acute pulmonary embolism after treatment with intravenous tissue
plasminogen activator. J Am Coll Cardiol 1987;10:971-8.
[91] Dong BR, Hao Q, Yue J, Wu T, Liu GJ. Thrombolytic therapy for
pulmonary embolism. Cochrane Database Syst Rev 2009;8(3):
CD004437.
[92] Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis
compared with heparin for the initial treatment of pulmonary
embolism: a meta-analysis of the randomized controlled trials.
Circulation 2004;110:744-9.
[93] Meyer JA. Friedrich Trendelenburg and the surgical approach to
massive pulmonary embolism. Arch Surg 1990;125:1202-5.
[94] Cooley DA, Beall AC Jr, Alexander JK. Acute massive pulmonary
embolism. Successful surgical treatment using temporary cardiopul-
monary bypass. JAMA 1961;177:283-6.
[95] Yalamanchili K, Fleisher AG, Lehrman SG, et al. Open pulmonary
embolectomy for treatment of major pulmonary embolism. Ann
Thorac Surg 2004;77:819-23.
[96] Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment
of massive pulmomary embolism: results in 47 consecutive patients
after rapid diagnosis and aggressive surgical approach. J Thorac
Cardiovasc Surg 2005;129:1018-23.
[97] Dauphine C, Omari B. Pulmonary embolectomy for acute massive
pulmonary embolism. Ann Thorac Surg 2005;79:1240-4.
[98] Sádaba JR, Greco E, Alvarez LA, Pulitani I, Juaristi A, Goiti JJ. The
surgical option in the management of acute pulmonary embolism. J
Card Surg 2008;23:729-32.
[99] Clarke DB. Pulmonary embolectomy re-evaluated. Ann R Coll Surg
Engl 1981;63:8-24.
[100] Mattox KL, Feldtman RW, Beal AC Jr, DeBakey ME. Pulmonary
embolectomy for acute massive pulmonary embolism. Ann Surg
1982;195:726-31.
[101] Gray HH, Morgan JM, Paneth M, Miller GA. Pulmonary
embolectomy for acute massive pulmonary embolism: an analysis
of 71 cases. Br Heart J 1988;60:196-200.
[102] Meyer G, Tamisier D, Sors H, et al. Pulmonary embolectomy: a 20-
year experience at one center. Ann Thorac Surg 1991;51:232-6.
[103] Kuo WT, van den Bosch MA, Hofman LV, Louie JD, Kothary N, Sze
DY. Catheter-directed embolectomy, fragmentation, and thrombo-
lysis for the treatment of massive pulmonary embolism after failure of
systemic thrombolysis. Chest 2008;134:250-4.
[104] Comfere TB, Sprung J, Case KA, et al. Predicators of mortality
following symptomatic pulmonary embolism in patients undergoing
noncardiac surgery. Can J Anaesth 2007;54:634-41.
[105] Knudson MM, Collins JA, Goodman SB, McCrory DW. Thrombo-
embolism following multiple trauma. J Trauma 1992;32:2-11.
[106] Kucher N, Goldhaber SZ. Management of massive pulmonary
embolism. Circulation 2005;112:e28-32.
[107] Pengo V, Lensing AW, Prins MH, et al; Thromboembolic Pulmonary
Hypertension Study Group. Incidence of chronic thromboembolic
pulmonary hypertension after pulmonary embolism. N Engl J Med
2004;350:2257-64.
[108] Schulman S, Lindmarker P, Holmström M, et al. Post-thrombotic
syndrome, recurrence, and death 10 years after the first episode of
venous thromboembolism treated with warfarin for 6 weeks or 6
months. J Thromb Haemost 2006;4:734-42.
[109] Nagahiro I, Andou A, Aoe M, Sano Y, Date H, Shimizu N.
Intermittent pneumatic compression is effective in preventing
symptomatic pulmonary embolism after thoracic surgery. Surg
Today 2004;34:6-10.
[110] Sugarbaker DJ, Jaklitsch MT, Beuno R, et al. Prevention, early
detection, and management of complications after 328 consecutive
extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004;128:
138-46.
165
[111] Rasmussen MS, Jorgensen LN. Postoperative fatal pulmonary
embolism in a general surgical department. Am J Surg 1995;169:214-6.
[112] Satiani B, Kuhns M, Evans WE. Deep venous thrombosis following
operations upon the abdominal aorta. Surg Gynecol Obstet 1980;151:
241-5.
[113] Bani-Hani M, Titi M, Al-Khaffaf H. Deep venous thrombosis after
arterial surgery: a literature review. Eur J Vasc Endovasc Surg
2008;36:565-73.
[114] Moreano EH, Hutchison JL, McCulloch TM, Graham SM, Funk GF,
Hoffman HT. Incidence of deep venous thrombosis and pulmonary
embolism in otolaryngology-head and neck surgery. Otolaryngol
Head Neck Surg 1998;118:777-84.
[115] Chen C, Disa J, Cordeiro P, Pusic AL, McCarthy CM, Mehrara BJ.
The incidence of venous thromboembolism after oncologic head and
neck reconstruction. Ann Plast Surg 2008;60:476-9.
[116] Martino MA, Borges E, Williamson E, et al. Pulmonary embolism
after major abdominal surgery in gynecologic oncology. Obstet
Gynecol 2006;107:666-71.
[117] Cisek LJ, Walsh PC. Thromboembolic complications following
radical retropubic prostatectomy: influence of external sequential
pneumatic compression devices. Urology 1993;42:406-8.
[118] Dillioglugil O, Liebman BD, Liebman NS, Kattan MW, Rosas AL,
Scardino PT. Risk factors for complications and mortality after
radical retropubic prostatectomy. J Urol 1997;157:1760-7.
[119] Pettus JA, Eggener SE, Shabsigh A, et al. Perioperative clinical
thromboembolic events after radical or partial nephrectomy. Urology
2006;68:988-92.
[120] Epstein NE. A review of the risks and benefits of differing
prophylaxis regimens for the treatment of deep vein thrombosis
and pulmonary embolism in neurosurgery. Surg Neurol 2005;64:
295-302.
[121] Constantini S, Kornowski R, Pomeranz S, Rappaport ZH. Throm-
boembolic phenomena in neurosurgical patients operated upon for
primary and metastatic brain tumors. Acta Neurochir 1991;109:93-7.
[122] Danish SF, Burnett MG, Ong JG, Sonnad SS, Maloney-Wilensky E,
Stein SC. Prophylaxis for deep vein thrombosis in craniotomy
patients: a decision analysis. Neurosurgery 2005;56:1286-94.
[123] Chibbaro S, Tacconi L. Safety of deep venous thrombosis
prophylaxis with low molecular weight heparin in brain surgery.
Prospective study on 746 patients. Surg Neurol 2008;70:117-21.
[124] Blaszyk H, Björnsson J. Factor V leiden and morbid obesity in fatal
postoperative pulmonary embolism. Arch Surg 2000;135:1410-3.
[125] O'Malley KF, Ross SE. Pulmonary embolism in major trauma
patients. J Trauma 1990;30:748-50.
[126] Waring WP, Karunas RS. Acute spinal cord injuries and the
incidence of clinically occurring thromboembolic disease. Paraplegia
1991;29:8-16.
[127] Myllynen P, Kammonen M, Rokkanen P, Böstman O, Lalla M,
Laasonen E. Deep venous thrombosis and pulmonary embolism in
patients with acute spinal cord injury: a comparison with nonpar-
alyzed patients immobilized due to spinal fractures. J Trauma
1985;25:541-3.
[128] Walsh JJ, Tribe CR. Phlebothrombosis and pulmonary embolism in
paraplegia. Paraplegia 1965;3:209-13.
[129] Green D, Lee MY, Lim AC, et al. Prevention of thromboembolism
after spinal cord injury using low-molecular-weight heparin. Ann
Intern Med 1990;113:571-4.
[130] Green D, Chen D, Chmiel JS, et al. Prevention of thromboembolism
in spinal cord injury: role of low molecular weight heparin. Arch
Phys Med Rehabil 1994;75:290-2.
[131] Anderson FA Jr, Spencer FA. Risk factors for venous thromboem-
bolism. Circulation 2003;107(23 Suppl 1):I9-I16.
[132] Stead LG, Stead SM, Kaufman MS. First Aid for the Emergency
Medicine Clerkship: A Student Guide. New York: McGraw-Hill;
2001. p. 118.